227 related articles for article (PubMed ID: 18684702)
1. Tigecycline pharmacokinetic/pharmacodynamic update.
MacGowan AP
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i11-6. PubMed ID: 18684702
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Bradford PA; Weaver-Sands DT; Petersen PJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline: a review of a new glycylcycline antibiotic.
Scheinfeld N
J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
[TBL] [Abstract][Full Text] [Related]
5. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline: a new glycylcycline for treatment of serious infections.
Noskin GA
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
[TBL] [Abstract][Full Text] [Related]
8. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetic and pharmacodynamic profile of tigecycline.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S333-40. PubMed ID: 16080071
[TBL] [Abstract][Full Text] [Related]
10. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Bhavnani SM; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):155-9. PubMed ID: 19150707
[TBL] [Abstract][Full Text] [Related]
11. Tigecycline: what is it, and where should it be used?
Livermore DM
J Antimicrob Chemother; 2005 Oct; 56(4):611-4. PubMed ID: 16120626
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline-induced acute pancreatitis: case report and literature review.
Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.
Peterson LR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):163-4. PubMed ID: 16105559
[No Abstract] [Full Text] [Related]
15. What role for tigecycline in infections?
BMJ Group
Drug Ther Bull; 2008 Aug; 46(8):62-4. PubMed ID: 18687585
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline: a critical analysis.
Stein GE; Craig WA
Clin Infect Dis; 2006 Aug; 43(4):518-24. PubMed ID: 16838243
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
18. A review of tigecycline--the first glycylcycline.
Peterson LR
Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
Grolman DC
Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
[TBL] [Abstract][Full Text] [Related]
20. One-year experience with tigecycline in treating serious infections in severely burned patients.
Lipový B; Rihová H; Hanslianová M; Brychta P
Acta Chir Plast; 2009; 51(3-4):69-71. PubMed ID: 20514890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
